0000905148-24-000585.txt : 20240212
0000905148-24-000585.hdr.sgml : 20240212
20240212214535
ACCESSION NUMBER: 0000905148-24-000585
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240208
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Kane Kieran
CENTRAL INDEX KEY: 0001828131
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39659
FILM NUMBER: 24622373
MAIL ADDRESS:
STREET 1: 2970 WILDERNESS PLACE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODESIX INC
CENTRAL INDEX KEY: 0001439725
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 203986492
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2970 WILDERNESS PLACE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 303-417-0500
MAIL ADDRESS:
STREET 1: 2970 WILDERNESS PLACE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
form4.xml
X0508
4
2024-02-08
0001439725
BIODESIX INC
BDSX
0001828131
O'Kane Kieran
919 WEST DILLON RD
LOUISVILLE
CO
80027
true
Chief Commercial Officer
false
Common Stock
2024-02-08
4
M
0
32024
A
79736
D
Common Stock
2024-02-09
4
S
0
6319
1.9166
D
73417
D
Common Stock
2024-02-12
4
S
0
5412
1.6647
D
68005
D
Restricted Stock Units
2024-02-08
4
A
0
64381
0
A
Common Stock
64381
64381
D
Stock Options (Right to buy)
1.99
2024-02-08
4
A
0
128761
0
A
2034-02-07
Common Stock
128761
128761
D
Restricted Stock Units
2024-02-08
4
M
0
1490
0
D
Common Stock
1490
11915
D
Restricted Stock Units
2024-02-08
4
M
0
30534
0
D
Common Stock
30534
91601
D
Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.8191 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
This option vests in a series of forty-eight successive equal monthly installments measured from January 15, 2024, generally subject to the Reporting Person's continuous service through each applicable vesting date.
These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
/s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane
2024-02-12